CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Regnum Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Regnum Corp
600 THIRD AVENUE, 10TH
Phone: (917) 647-1498p:917 647-1498 NEW YORK, NY  10016  United States Ticker: RGMPRGMP

Business Summary
Regnum Corp. is a biopharmaceutical company. The Company is focused on late-stage commercial and clinical development programs. The Company is engaged in developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, tolerability, or cost and accessibility of available therapeutic options. The Company's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. leronlimab is used as a platform drug for a variety of HIV indications. The target of leronlimab is the immunologic receptor C-C chemokine receptor type 5 (CCR5). Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202212/31/2021YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Business Names
Business Name
RGMP
SevenScore Pharmaceuticals LLC

General Information
Outstanding Shares: 22,950,000 (As of 5/20/2022)
Shareholders: 3
Stock Exchange: OTC
Federal Tax Id: 820832447


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 19, 2022